Biodexa Expands eRapa Access for FAP Patients via Tanner Pharma Partnership

Event summary

  • Biodexa partners with Tanner Pharma Group to launch a global early access program for eRapa, targeting Familial Adenomatous Polyposis (FAP) patients.
  • The program allows clinicians to prescribe eRapa outside of clinical trials for the first time, subject to local legislation and funding availability.
  • Biodexa will generate Real World Data to better understand FAP patient challenges, underscoring its long-term commitment to the therapy area.
  • eRapa, a proprietary oral formulation of rapamycin, has received Orphan Designation in the US and is supported by a $20 million grant from CPRIT for its Phase 3 trial.

The big picture

Biodexa's strategic partnership with Tanner Pharma Group expands access to eRapa for FAP patients, addressing a critical unmet need in gastrointestinal cancer treatment. The move aligns with broader industry trends toward patient-centric drug development and real-world evidence collection, potentially accelerating regulatory approvals and market adoption. The $20 million grant from CPRIT underscores the therapeutic and commercial potential of eRapa, positioning Biodexa as a key player in the orphan drug space.

What we're watching

Regulatory Dynamics
How local legislation and funding availability will impact the global rollout of the early access program.
Clinical Validation
Whether the Real World Data generated will support eRapa's efficacy and safety profile beyond clinical trial settings.
Competitive Positioning
The pace at which Biodexa can differentiate eRapa in the FAP treatment landscape, given the lack of approved therapeutic options.

Related topics

Partnership